The Oncometabolite 5'-Deoxy-5'-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 24 02 2020
accepted: 05 08 2020
entrez: 30 10 2020
pubmed: 31 10 2020
medline: 7 5 2021
Statut: epublish

Résumé

Tumor cells develop various mechanisms to escape immune surveillance. In this context, oncometabolites secreted by tumor cells due to deregulated metabolic pathways, have been in the spotlight of researchers during the last years. 5'-Deoxy-5'-methylthioadenosine (MTA) phosphorylase (MTAP) deficiency in tumors results in the accumulation of MTA within the tumor microenvironment and thereby negatively influencing immune functions of various immune cells, including T and NK cells. The influence of MTA on T cell activation has been recently described in more detail, while its impact on NK cells is still largely unknown. Therefore, we aimed to illuminate the molecular mechanism of MTA-induced NK cell dysfunction. NK cell cytotoxicity against target cells was reduced in the presence of MTA in a dose-dependent manner, while NK cell viability remained unaffected. Furthermore, we revealed that MTA blocks NK cell degranulation and cytokine production upon target cell engagement as well as upon antibody stimulation. Interestingly, the immune-suppressive effect of MTA was less pronounced in healthy donors harboring an expansion of NKG2C

Identifiants

pubmed: 33123121
doi: 10.3389/fimmu.2020.02128
pmc: PMC7573074
doi:

Substances chimiques

CD57 Antigens 0
Cytokines 0
Deoxyadenosines 0
FCGR3B protein, human 0
GPI-Linked Proteins 0
KLRC2 protein, human 0
Lysosomal-Associated Membrane Protein 1 0
NF-kappa B 0
NK Cell Lectin-Like Receptor Subfamily C 0
Receptors, IgG 0
Thionucleosides 0
5'-methylthioadenosine 634Z2VK3UQ
Interferon-gamma 82115-62-6
PRMT5 protein, human EC 2.1.1.319
Protein-Arginine N-Methyltransferases EC 2.1.1.319
Purine-Nucleoside Phosphorylase EC 2.4.2.1
5'-methylthioadenosine phosphorylase EC 2.4.2.28

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2128

Informations de copyright

Copyright © 2020 Jacobs, Schlögl, Strobl, Völkl, Stoll, Mougiakakos, Malmberg, Mackensen and Aigner.

Références

Cancer Res. 2015 Sep 15;75(18):3692-5
pubmed: 26337909
Biochem Biophys Res Commun. 1981 May 29;100(2):523-31
pubmed: 6791639
Eur J Immunol. 2014 Jul;44(7):2074-84
pubmed: 24752800
PLoS Pathog. 2014 Oct 16;10(10):e1004441
pubmed: 25329659
Front Immunol. 2019 Aug 29;10:2078
pubmed: 31555287
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Mol Cell Biol. 2015 Jan;16(1):5-17
pubmed: 25491103
Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G352-62
pubmed: 15064230
Eur J Surg Oncol. 2014 Sep;40(9):1143-50
pubmed: 24969958
Cell Rep. 2016 May 3;15(5):1088-1099
pubmed: 27117418
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Dec 1;876(1):123-8
pubmed: 18996776
J Exp Med. 2005 Aug 1;202(3):371-7
pubmed: 16061726
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Immunol Today. 1990 Jul;11(7):237-44
pubmed: 2201309
Biochem J. 1983 Feb 15;210(2):429-35
pubmed: 6407475
Blood. 2006 Jan 1;107(1):159-66
pubmed: 16150947
BMC Cancer. 2010 Jun 08;10:265
pubmed: 20529342
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Hepatology. 2004 Apr;39(4):1088-98
pubmed: 15057913
Int J Cancer. 1998 Jan 5;75(1):51-6
pubmed: 9426690
Blood. 2004 Dec 1;104(12):3664-71
pubmed: 15304389
Am J Pathol. 2003 Aug;163(2):683-90
pubmed: 12875987
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13516-21
pubmed: 23904475
Cancer Res. 2006 Aug 1;66(15):7758-65
pubmed: 16885379
Cell Rep. 2016 Apr 19;15(3):574-587
pubmed: 27068473
J Med Chem. 1980 Apr;23(4):347-57
pubmed: 6991690
Cancer Immunol Res. 2017 Aug;5(8):654-665
pubmed: 28637877
FEBS Lett. 1981 Apr 20;126(2):236-40
pubmed: 7238872
Science. 2016 Mar 11;351(6278):1214-8
pubmed: 26912360
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
Cancer Biol Ther. 2011 Apr 1;11(7):627-32
pubmed: 21301207
Science. 2016 Mar 11;351(6278):1208-13
pubmed: 26912361
J Leukoc Biol. 2019 May;105(5):955-971
pubmed: 30848847
J Immunol Methods. 2011 Mar 7;366(1-2):106-18
pubmed: 21295038
Front Immunol. 2014 Apr 23;5:187
pubmed: 24795729
PLoS One. 2014 Aug 12;9(8):e104210
pubmed: 25117662
Nat Cell Biol. 2019 Feb;21(2):226-237
pubmed: 30692625
Oncoimmunology. 2018 Mar 26;7(7):e1445454
pubmed: 29900057
J Med Chem. 1977 Apr;20(4):500-5
pubmed: 850235
J Immunol Methods. 2007 Aug 31;325(1-2):51-66
pubmed: 17617419
Eur J Cancer. 2014 Oct;50(15):2714-24
pubmed: 25087184
J Immunol. 2012 Nov 15;189(10):5082-8
pubmed: 23077239
Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30
pubmed: 15313459
Carcinogenesis. 2007 Jan;28(1):21-7
pubmed: 16774947
Blood. 2010 Mar 18;115(11):2167-76
pubmed: 19965656
Exp Dermatol. 2010 Aug;19(8):e251-7
pubmed: 20500769
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
Ann Neurol. 2006 Sep;60(3):323-34
pubmed: 16786535
Cold Spring Harb Perspect Biol. 2019 Mar 1;11(3):
pubmed: 29661791
Blood. 2011 Sep 22;118(12):3347-9
pubmed: 21768303
Eur J Immunol. 2013 May;43(5):1133-41
pubmed: 23552990
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Blood. 2010 Nov 11;116(19):3853-64
pubmed: 20696944
Scand J Immunol. 1984 Dec;20(6):511-8
pubmed: 6096962
Carcinogenesis. 2012 Feb;33(2):427-35
pubmed: 22159228
Mol Cancer Ther. 2020 Feb;19(2):409-419
pubmed: 31712395
Oncoimmunology. 2016 Jun 10;5(8):e1184802
pubmed: 27622058
J Cell Biochem. 2009 Feb 1;106(2):210-9
pubmed: 19097084

Auteurs

Benedikt Jacobs (B)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Sebastian Schlögl (S)

Department of Anesthesiology, Intensive Care and Pain Therapy, General Hospital Fürth, Fürth, Germany.

Carolin Dorothea Strobl (CD)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Simon Völkl (S)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Andrej Stoll (A)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Dimitrios Mougiakakos (D)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Karl-Johan Malmberg (KJ)

Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Andreas Mackensen (A)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Michael Aigner (M)

Department of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU), University Hospital Erlangen, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH